Clonidine is an α-adrenergic agonist which may alleviate emerging symptoms in Tourette syndrome, an observation that has fueled speculation regarding involvement of stress-sensitive central noradrenergic systems in this disorder. We conducted a retrospective study of 53 juvenile patients with Tourette syndrome to assess predictors of short-term behavioral and tic response to oral clonidine and to examine the relationship, if any, among pretreatment blood pressure, tic severity, and clonidine response. When adverse effects were considered, older subjects experienced a better therapeutic response to clonidine, independent of dose. Improvement in symptoms of attention-deficit hyperactivity disorder was associated with a longer duration of vocal tics before treatment. Baseline sitting diastolic blood pressure was directly correlated with measures of tic severity but not with tic response to clonidine. The findings (1) provide indirect support for involvement of central noradrenergic systems in tic expression; (2) suggest that emergence of a tic-related neurophysiologic dysfunction may be necessary for optimal behavioral response to clonidine in Tourette syndrome; and (3) provide broad guidelines for the clinician considering clonidine therapy for pediatric patients with Tourette syndrome, particularly those with comorbid attention-deficit hyperactivity disorder. (J Child Neurol 1996; 11:93-97).
Get full access to this article
View all access options for this article.
References
1.
Kurlan R.: Tourette's syndrome: Current concepts. Neurology1989;39:1625-1630.
2.
Comings DE, Comings BG: Tourette syndrome and attention deficit disorder with hyperactivity: Are they genetically related?JAm Acad Child Psychiatry1984;23:138-146.
3.
Comings DE, Comings BG: A controlled study of Tourette syndrome. I. Attention deficit disorder, learning disorders and school problems. Am J Hum Genet1987;41:701-741.
4.
Singer HS, Walkup JT: Tourette syndrome and other tic disorders: Diagnosis, pathophysiology, and treatment. Medicine1991; 70:15-32.
5.
Cohen DJ, Leckman JF: Developmental psychopathology and neurobiology of Tourette's syndrome . J Am Acad Child Adolesc Psychiatry1994 ;33:2-15.
6.
Pauls DL, Leckman JF, Cohen DJ: Familial relationship between Gilles de la Tourette's syndrome, attention deficit disorder, learning disabilities, speech disorders, and stuttering . J Am Acad Child Adolesc Psychiatry1993 ;32:1044-1050.
7.
Towbin KE, Cohen DJ, Leckman JF: Tic disorders, in Karasu TB (ed): Treatments of Psychiatric Disorders. Washington, DC, American Psychiatric Association, 1989, pp 687-714.
8.
Cohen DJ, Young JG, Nathanson JA, Shaywitz BA: Clonidine in Tourette's syndrome. Lancet1979 ;2:551-553.
9.
Stefl MD: The Ohio Tourette Study: An Investigation of the Special Service Needs of Tourette Syndrome Patients. Cincinnati, Tourette Syndrome Association of Ohio, 1983 , p 31.
10.
Leckman JF, Hardin MT, Riddle MA, et al: Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry1991; 48:324-328.
11.
Leckman JF, Cohen JC, Detlor J., et al: Clonidine in the treatment of Tourette syndrome: A review of data. Adv Neurol1982; 35:391-401.
12.
Jagger J., Prusoff BA, Cohen DJ, et al: The epidemiology of Tourette's syndrome: A pilot study. Schizophr Bull1982;8: 267-278.
13.
Leckman JF, Cohen DJ, Price RA, et al: The pathogenesis of Tourette syndrome: A review of data and hypotheses, in Shah NS, Donald AG (eds): Movement Disorders. New York, Plenum, 1986 , pp 257-272.
14.
Goetz CG: Clonidine and clonazepam in Tourette syndrome. Adv Neurol1992;58:245-251.
15.
Leckman JF, Walkup JT, Cohen DJ: Clonidine treatment of Tourette's syndrome, in Cohen DJ, Bruun RD, Leckman JF (eds): Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York, John Wiley, 1988, pp 291-301.
16.
Leckman JF, Riddle MA, Hardin MT, et al: The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. JAm Acad Child Adolesc Psychiatry1989;28:566-573.
17.
Leckman JF, Towbin KE, Ort SI, Cohen DJ: Clinical assessment of tic disorder severity, in Cohen DJ, Bruun RD , Leckman JF (eds): Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment . New York, John Wiley, 1988, pp 55-78.
18.
Shapiro AK, Shapiro ES, Young JG, Feinberg TE: Gilles de la Tourette Syndrome, 2nd ed. New York, Raven Press, 1988, p 510.
19.
Hunt RD, Minderaa RB, Cohen DJ: Clonidine benefits children with attention deficit disorder and hyperactivity: Report of a double blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry1985;24:617-629.
20.
Hunt RD, Minderaa RB, Cohen DJ: The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: A comparison with placebo and methylphenidate. Psychopharmacol Bull1986;22:229-236.
21.
Steingard R. , Biederman J., Spencer T., et al: Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry1993;32:350-353.
22.
Cohen DJ, Riddle MA, Leckman JF: Pharmacotherapy of Tourette's syndrome and associated disorders. Psychiatr Clin North Am1992;15:109-129.
23.
Steingard RJ , Goldberg M., Lee D., DeMaso DR: Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD . J Am Acad Child Adolesc Psychiatry1994;33:394-399.
24.
Leckman JF, Cohen DJ: Descriptive and diagnostic classification of tic disorders, in Cohen DJ, Bruun RD , Leckman JF (eds): Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment . New York, John Wiley, 1988, pp 3-19.
25.
Bruun RD: The natural history of Tourette's syndrome, in Cohen DJ, Bruun RD, Leckman JF (eds): Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York, John Wiley, 1988, pp 21-39.
26.
Svensson TH , Bunney BS, Aghajanian GK: Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res1975;92:291-306.
27.
Grenhoff J. , Svensson TH: Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur J Phannacol1989; 165: 11-18.
28.
Geyer MA, Lee Ehy: Effects of clonidine, piperoxane and locus coeruleus lesion on the serotonergic and dopaminergic systems in raphe and caudate nucleus. Biochem Pharmacol1984;33: 3399-3404.
29.
Zametikin AJ , Rapoport JL: Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years?J Am Acad Child Adolesc Psychiatry1987;26:676-686.
30.
Levy F., Hobbes G.: The action of stimulant medication in attention deficit disorder with hyperactivity: Dopaminergic, noradrenergic, or both?J Am Acad Child Adolesc Psychiatry1988; 27:802-805.
31.
Leckman JF, Riddle MA, Cohen DJ: Pathobiology of Tourette's syndrome, in Cohen DJ, Bruun RD, Leckman JF (eds): Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York, John Wiley, 1988, pp 103-116.
32.
Young JG, Cohen DJ, Hattox SE, et al: Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's syndrome: Preliminary report. Life Sci1981;29: 1467-1475.
33.
Garfinkel BD , Wender P., Sloman L., O'Neill I.: Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. JAm Acad Child Psychiatry1983;22:343-348.
34.
Rapoport J. , Quinn PO, Bradbard G., et al: Imipramine and methylphenidate treatments of hyperactive boys. Arch Gen Psychiatry1974 ;30:789-793.
35.
Fredrikson M., Mathews KA: Cardiovascular responses to behavioral stress and hypertension: A meta-analytic review. Ann Behav Med1990;12:30-39.
36.
Lamprecht F. , Eichelman B., Thoa NB, et al: Rat fighting behavior: Serum dopamine-beta-hydroxylase and hypothalamic tyrosine hydroxylase . Science1972;177:1214-1215.
37.
Lake CR, Ziegler MG, Murphy DL: Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism. Arch Gen Psychiatry1977 ;34:533-536.
38.
Cohen DJ, Johnson WT: Cardiovascular correlates of attention in normal and psychiatrically disturbed children: Blood pressure, peripheral blood flow and peripheral vascular resistance . Arch Gen Psychiatry1977;34:561-567.
39.
Frankhauser MP, Karumanchi VC, German ML, et al: A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism . J Clin Psychiatry1992;53:77-82.
40.
Koslow SH, Cross CK: Cerebrospinal fluid monoamine metabolites in Tourette syndrome and their neuroendocrine implica tions. Adv Neurol1982;35:185-197.
41.
Singer HS, Butler IJ, Tune LE, et al: Dopaminergic dysfunction in Tourette syndrome. Ann Neurol1982;12:361-366.
42.
Leckman JF, Ort L., Cohen DJ, et al: Rebound phenomenon in Tourette's syndrome after abrupt withdrawal of clonidine: Behavioral, cardiovascular and neurochemical effects. Arch Gen Psychiatry1986;43:1168-1176.
43.
Leckman JF, Pauls DL, Peterson BS, et al: Pathogenesis of Tourette's syndrome: Clues from the clinical phenotype and natural history. Adv Neurol1992;58:15-23.
44.
Erenberg G. , Cruse RP, Rothner AD: Gilles de la Tourette's syndrome: Effects of stimulant drugs. Neurology1985;35:1346-1348.
45.
Sverd J., Gadow KD, Paolicelli LM: Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette syndrome. J Am Acad Child Adolesc Psychiatry1989;28:574-579.
